Your session is about to expire
← Back to Search
Depemokimab for Asthma (SWIFT-2 Trial)
SWIFT-2 Trial Summary
This trial will test a new drug to see if it can help people with severe asthma that isn't well controlled and has a lot of eosinophils.
SWIFT-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSWIFT-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SWIFT-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with asthma for 2 years or more, following NHLBI or GINA guidelines.I have used asthma medication recently.I have been diagnosed with asthma for 2 years or more, according to NHLBI or GINA guidelines.Your heart's electrical activity, called the QT interval, is longer than normal.I've needed steroids for asthma attacks at least twice in the last year despite using inhalers.I use a medium to high dose inhaler for my asthma daily.My asthma medication dose or type hasn't changed recently.I have a condition that increases my eosinophil count.I am 12-17 years old with specific lung function test results below normal.I have a significant lung condition that is not asthma.I do not have any uncontrolled serious health issues.I am 12 years old or older.I've had 2 or more severe asthma attacks in the last year despite using my regular medication.I have breathing issues with less than 80% normal lung function.I am 12 years old or older.I do not have cirrhosis or current unstable liver/biliary disease.I have been diagnosed with vasculitis.I likely have asthma with an eosinophilic phenotype.I've been on a second asthma medication besides inhaled steroids for over 3 months.My cancer has been in remission for less than a year, except for skin cancer.You have a heart condition, smoke, or can't tolerate certain medications.I have not had a severe asthma attack in the last week.My lung function tests show I have airflow obstruction.I have asthma with a high number of eosinophils.
- Group 1: Participants receiving GSK3511294 (Depemokimab)
- Group 2: Participants receiving Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there many sites running this clinical trial in Canada?
"50 different medical centres are enrolling patients for this clinical trial. If you decide to participate in the study, please choose a location nearest to you from the list of 50 sites. This will minimize travel requirements."
What is GSK3511294's (Depemokimab) standing with the FDA?
"Given that this is a Phase 3 trial with both efficacy and safety data, GSK3511294 (Depemokimab) was given a score of 3 for safety."
Can people with the qualifying medical condition join this research study at this time?
"This study is looking for patients, as indicated on clinicaltrials.gov. The listing was first posted on 3/11/2021 and last updated on 10/21/2022."
Can you give me an estimate of how many people will be participating in this trial?
"Yes, according to the clinicaltrials.gov website, this trial is open for recruitment. The study was originally posted on March 11th, 2021 and updated on October 21st, 2022. They are looking for 375 participants across 50 different locations."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger